PD-L1 protein levels could be an important biomarker to predict response to immunotherapy in NSCLC patients.
Among patients with non-small cell lung cancer (NSCLC) treated with the investigational immune checkpoint inhibitor MK-3475, those whose tumors had high levels of the protein PD-L1 had significantly better outcomes. These results from a phase I clinical trial were presented at the American Association for Cancer Research 2014 Annual Meeting, in San Diego, California.
Preliminary data from the trial, which were reported earlier this year, showed that MK-3475 treatment was well tolerated and led to durable, objective responses in previously treated patients with NSCLC, particularly those with tumors found to have high levels of PD-L1 prior to treatment.
The latest results extend these data, showing that at 6 months after starting treatment, 41% of patients whose tumors had high levels of PD-L1 had no disease progression, compared with 17% of those whose tumors had low levels of PD-L1. Similarly, 72% of patients whose tumors had high levels of PD-L1 were alive at this time, compared with 53% of those whose tumors had low levels of PD-L1.
Read the complete report here: http://bit.ly/1mQXGWK